Is Metformin Used Topically for Hair Loss, or Only as an Oral Tablet?

Metformin, a drug widely known for treating type 2 diabetes, has become the subject of speculation in hair loss research. The question often arises: can it be used topically on the scalp to promote hair growth, or is it limited to oral use? Approved metformin products are oral tablets only; every reported topical use is compounded and experimental, and the published human data are limited to a handful of uncontrolled case reports.

What Metformin Does — And Why Researchers Are Interested in the Scalp

Metformin primarily acts on the liver and peripheral tissues to lower blood sugar levels. It reduces hepatic glucose production and improves the body's sensitivity to insulin. Beyond its metabolic role, researchers report that metformin activates a cellular pathway known as AMP-activated protein kinase (AMPK). AMPK is a key regulator of energy balance in cells, and its activation can influence inflammation, fibrosis (the formation of scar-like tissue), and cellular stress — all processes that are relevant to hair follicle health.

Hair follicles are metabolically active structures, requiring high energy for continuous cell division and hair fiber production. Chronic inflammation, fibrosis, and hormonal imbalances can disrupt this cycle and cause various types of hair loss, from androgenetic alopecia (pattern baldness) to cicatricial (scarring) alopecias. Because metformin acts on some of the same cellular stress and inflammatory pathways, researchers began testing whether it might restore follicular function when applied directly to the scalp.

From Diabetes to Dermatology: How the Research Started

The earliest clues came from laboratory and animal studies. In a 2022 paper in Skin Pharmacology and Physiology, Sun and colleagues exposed three-dimensional aggregates of epidermal and dermal cells taken from newborn mice — dermal papilla cells are the specialized cells at the base of hair follicles — to metformin, grafted them onto mice, and report that it promoted the hair-inductive activity of those aggregates. The work used mouse cells, in the laboratory and in grafted mice, not human tissue. Such experiments can show a biological mechanism; they cannot show a real-world result.

In 2025, Mai and colleagues reported in Research that a topical metformin nanosystem promoted hair growth in a mouse model of androgenetic alopecia, with regrowth assessed photographically and by microscopic examination of follicles. Mouse skin differs substantially from human scalp tissue, and hair-growth findings in rodent models frequently fail to reproduce in people.

What Human Studies Tell Us (and What They Don't)

Human evidence for topical metformin is sparse and consists of case reports. In 2020, Araoye, Thomas and Aguh described in JAAD Case Reports two patients with recalcitrant central centrifugal cicatricial alopecia (CCCA) — a scarring form of hair loss — who showed hair regrowth after using a 10% compounded topical metformin preparation. The assessment relied on clinical observation and photographic comparison, and at least one of the two patients continued other treatments (steroid injections and minoxidil) at the same time. Without a control group, the regrowth cannot be attributed to metformin alone.

A 2025 case series in the same journal, from Williams and colleagues, described three patients who used topical metformin as an adjuvant (an addition) alongside standard CCCA therapies such as oral antibiotics and topical minoxidil, and reported improvement in hair density. This again shows how hard it is to isolate one agent's effect when several are used together.

Notably, the most-cited clinical report on metformin and scalp disease used the oral drug, not a topical one. In a retrospective case series in JAMA Dermatology, Bao and colleagues (2024) added extended-release oral metformin, 500 mg once daily, to the existing regimens of 12 Black women with biopsy-confirmed, treatment-refractory CCCA. The authors report that after at least six months, nine participants had improvement in scalp pain, inflammation and/or itch, and six showed clinical evidence of hair regrowth; paired scalp biopsies in four participants showed reduced expression of fibrosis-related genes. There was no randomized control group, the sample was small, and several outcomes were patient-reported, so the authors present it as a rationale for future trials rather than as proof of efficacy.

Overall, human data remain preliminary. Participant numbers are very low, treatment durations are short, and evaluation methods vary. Early findings suggest metformin may act on inflammation and fibrosis in scalp tissue, but no large-scale or blinded clinical trial has confirmed that either form regrows hair.

Oral Metformin: Does It Influence Hair?

Because oral metformin is widely prescribed for metabolic disorders, it has been studied indirectly in relation to hair. In polycystic ovary syndrome (PCOS), trials with hirsutism (unwanted body and facial hair) as the endpoint report improvement on metformin — but that is the opposite outcome from scalp regrowth, and in one randomized trial metformin improved insulin-resistance markers while producing almost no change in androgen levels. The approved product labelling for metformin lists it for glycaemic control in type 2 diabetes; it does not carry a hair-loss or hair-growth indication. In the other direction, at least one published case report describes alopecia that began during metformin treatment for PCOS and reversed after the drug was stopped.

In short, published evidence does not establish oral metformin as a hair loss treatment in either direction, and clinicians describe any hair effect as indirect and inconsistent.

The Current Scientific Position

Approved metformin products are oral tablets, and topical use for hair loss remains experimental. Laboratory and mouse studies provide a biological rationale, but the human evidence is not strong enough to place it in routine dermatological practice. There is no approved topical metformin product for hair loss; the published reports used pharmacy-compounded preparations prescribed and supervised by dermatologists in a clinical setting. Compounded strengths are not standardized, and the safety of long-term topical use — particularly systemic absorption and its metabolic effects — has not been characterized. This is not something to mix or source independently.

What Would Settle the Question

The open question is not whether topical metformin can theoretically influence hair growth, but whether it can do so safely, reproducibly, and better than options with trial evidence behind them. Answering it requires randomized, double-blind trials that measure efficacy, optimal concentration, vehicle formulation, duration of use, and systemic absorption. Until those exist, topical metformin is best described as an interesting but unproven idea — a hypothesis, not an established treatment.

Talk to a doctor, dermatologist or pharmacist before starting, stopping or combining metformin, in any form. Metformin is a prescription medicine, no form of it is approved for hair loss, and both oral and compounded topical use for hair would be off-label decisions for a prescribing clinician.

References

Sun, C., Hu, S. H., Dong, B. Q., Jiang, S., Miao, F., & Lei, T. C. (2022). Metformin promotes the hair-inductive activity of three-dimensional aggregates of epidermal and dermal cells self-assembled in vitro. Skin Pharmacology and Physiology, 35, 137-147. PMID 34883492. https://pubmed.ncbi.nlm.nih.gov/34883492/

Mai, Q., Lin, W., Qin, X., Cheng, G., Wang, C., & Yu, G. (2025). Robust metformin nanosystem promotes hair growth in androgenetic alopecia. Research, 8, 0780. PMID 40689361. https://doi.org/10.34133/research.0780

Araoye, E. F., Thomas, J. A. L., & Aguh, C. U. (2020). Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Reports, 6(2), 106-108. PMID 32016152. https://pubmed.ncbi.nlm.nih.gov/32016152/

Williams, M. N., Campbell, J. R., Thakker, S., & Chheda, M. (2025). Adjuvant use of topical metformin with standard therapies in recalcitrant central centrifugal cicatricial alopecia: A case series. JAAD Case Reports, 57, 74-77. PMID 40190490. https://pubmed.ncbi.nlm.nih.gov/40190490/

Bao, A., et al. (2024). Low-dose metformin and profibrotic signature in central centrifugal cicatricial alopecia. JAMA Dermatology, 160(11). PMID 39230880. https://pubmed.ncbi.nlm.nih.gov/39230880/

Acute alopecia due to metformin treatment for polycystic ovarian syndrome. (2006). Journal of Obstetrics and Gynaecology, 26(6), 584-585. PMID 17000520. https://pubmed.ncbi.nlm.nih.gov/17000520/

Harborne, L., Fleming, R., Lyall, H., Sattar, N., & Norman, J. (2003). Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 88(9), 4116-4123. PMID 12970273. https://pubmed.ncbi.nlm.nih.gov/12970273/